Content area

Abstract

Summary

With increasing attention on the essential roles of the tumour microenvironment in recent years, the nervous system has emerged as a novel and crucial facilitator of cancer growth. In this Review, we describe the foundational, translational, and clinical advances illustrating how nerves contribute to tumour proliferation, stress adaptation, immunomodulation, metastasis, electrical hyperactivity and seizures, and neuropathic pain. Collectively, this expanding knowledge base reveals multiple therapeutic avenues for cancer neuroscience that warrant further exploration in clinical studies. We discuss the available clinical data, including ongoing trials investigating novel agents targeting the tumour–nerve axis, and the therapeutic potential for repurposing existing neuroactive drugs as an anti-cancer approach, particularly in combination with established treatment regimens. Lastly, we discuss the clinical challenges of these treatment strategies and highlight unanswered questions and future directions in the burgeoning field of cancer neuroscience.

Details

Title
Therapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunities
Author
Shi, Diana D 1 ; Guo, Jimmy A 2 ; Hoffman, Hannah I 3 ; Su, Jennifer 4 ; Mino-Kenudson, Mari 5 ; Barth, Jaimie L 5 ; Schenkel, Jason M 6 ; Loeffler, Jay S 7 ; Shih, Helen A 7 ; Hong, Theodore S 7 ; Wo, Jennifer Y 7 ; Aguirre, Andrew J 8 ; Jacks, Tyler 9 ; Zheng, Lei 10 ; Wen, Patrick Y 11 ; Wang, Timothy C 12 ; Hwang, William L 4 

 Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA 
 Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA; School of Medicine, University of California, San Francisco, San Francisco, CA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Biological and Biomedical Sciences Program, Harvard University, Boston, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA 
 Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Biology, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA; Harvard-MIT Health Sciences and Technology Program, Harvard Medical School, Boston, MA, USA 
 Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Biology, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA 
 Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA 
 Department of Biology, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA 
 Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA 
 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA 
 Department of Biology, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA 
10  Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA 
11  Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA 
12  Division of Digestive and Liver Diseases, Columbia University Medical Center, New York, NY, USA 
Pages
e62-e74
Section
Review
Publication year
2022
Publication date
Feb 2022
Publisher
Elsevier Limited
ISSN
14702045
e-ISSN
14745488
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2624159757
Copyright
©2022. Elsevier Ltd